Table 4 Clinical characteristics of patients whose tumors acquired CDKN2A deletions at recurrence/progression
From: Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas
Patient ID # | Age at diagnosis (years) | Sex | Tumor Pathologic classification | Tumor location | Metastatic disease at diagnosis | Extent of surgery #1 | Time to first progression (months) | Time to surgery #2 (months) | Treatment received between diagnosis and gain of CDKN2A deletion | Current status (months from diagnosis to last follow-up) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 5 | F | Pilocytic astrocytoma | Diencephalic (hypothalamic/optic pathway) | No | STR | 20 | 26 | Chemotherapy (carboplatin, temozolomide) | Alive (104) |
2 | 12 | M | Pilocytic astrocytoma | Diencephalic (hypothalamic/optic pathway) | No | STR | 2 | 27 | Irradiation photon (50.4Â Gy)] | Alive (116) |
4 | 0.8 | F | Pilomyxoid astrocytoma | Diencephalic (hypothalamic) | No | Biopsy | 3.5 | 7 | Chemotherapy (carboplatin/vincristine, vinblastine, temozolomide, trametinib), additional debulking surgery | Alive (58) |
15 | 1 | M | Pilocytic astrocytoma | Posterior fossa | No | STR | 19 | 19 | Surgery only | Alive (93) |
18 | 5 | M | Pilocytic astrocytoma | Posterior fossa | No | STR | 17 | 17 | Surgery only | Alive (182) |
26 | 15 | M | Pilocytic astrocytoma | Cerebrum (Right temporal-parietal) | No | STR (biopsy, then STR 1Â week later) | 5.5 | 5.5 | Surgery only | Deceased (91; Drug overdose, unrelated to disease) |
41 | 0.4 | F | Desmoplastic infantile ganglioglioma | Cerebrum (Right frontal) | No | STR | 4 | 8 | Chemotherapy (carboplatin/vincristine) | Alive (94) |